JLE

Epileptic Disorders

MENU

Recommendations for treatment strategies in people with epilepsy during times of shortage of antiseizure medications Volume 24, numéro 5, October 2022

  • [1.] Finamore JM, Sperling MR, Zhan T, Nei M, Skidmore CT, Mintzer S. Seizure outcome after switching antiepileptic drugs: a matched, prospective study. Epilepsia 2016; 57: 1294-300.
  • [2.] Asadi-Pooya AA, Sperling MR. Antiepileptic drugs: a clinician’s manual, Third Edition, New York: Oxford University Press, 2022.
  • [3.] Lee SA, Heo K, Kim WJ, Song H-K, Kim S-E, Kim S-H, et al. Clinical feasibility of immediate overnight switching from slow-release carbamazepine to oxcarbazepine in Korean patients with refractory partial epilepsy. Seizure 2010; 19: 356-8.
  • [4.] Watkins L, O’Dwyer M, Oak K, Lawthom C, Maguire M, Thomas R, Shankar R. The evidence for switching dibenzazepines in people with epilepsy. Acta Neurol Scand 2020; 142: 121-30.
  • [5.] Mäkinen J, Rainesalo S, Peltola J. Transition from oxcarbazepine to eslicarbazepine acetate: a single center study. Brain Behav 2017; 7: e00634.
  • [6.] Schmid E, Kuchukhidze G, Kirschner M, Leitinger M, Höfler J, Rohracher A, et al. Overnight switching from oxcarbazepine to eslicarbazepine acetate: an observational study. Acta Neurol Scand 2017; 135: 449-53.
  • [7.] Steinhoff BJ, Trinka E, Wendling AS. Abrupter Austausch von retardiertem Oxcarbazepin gegen Eslicarbazepinacetat [Abrupt switch from extended-release oxcarbazepine to eslicarbazepine acetate]. Nervenarzt 2011; 82: 764-7.
  • [8.] Sankar R, Chung S, Perry MS, Kuzniecky R, Sinha S. Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. J Med Case Rep 2014; 8: 429.
  • [9.] Steinhoff BJ, Bacher M, Bucurenciu I, Hillenbrand B, Intravooth T, Kornmeier R, et al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy – A monocenter survey. Seizure 2017; 48: 11-4.
  • [10.] White PT, Plott D, Norton J. Relative anticonvulsant potency of primidone;a double blind comparison. Arch Neurol 1966; 14: 31-5.
  • [11.] Farkas V, Steinborn B, Flamini JR, Zhang Y, Yuen N, Borghs S, et al. Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures. Neurology 2019; 93: e1212-26.
  • [12.] Vossler DG, Knake S, O’Brien TJ, Watanabe S, Brock M, Steiniger-Brach B, et al. Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonicclonic seizures: a double-blind, randomised, placebocontrolled trial. J Neurol Neurosurg Psychiatry 2020; 91: 1067-75.
  • [13.] Kudriakovea TB, Sirota LA, Rozova GI, Gorkov BA. Autoinduction and steady-state pharmacokinetics of carbamazepine and it major metabolites. Br J Clin Pharmac 1992; 33: 611-5.
  • [14.] Punyawudho B, Cloyd JC, Leppik IE, Ramsay RE, Marino SE, Pennell PB, et al. Characterization of the time course of carbamazepine deinduction by an enzyme turnover model. Clin Pharmacokinet 2009; 48: 313-20.
  • [15.] Zheng Y, Zhou W, Guo X, Chi L, Chen C, Guo Z, et al. Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization. Expert Opin Drug Saf 2022; 1-7. Online ahead of print.
  • [16.] Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA. Drug hypersensitivity: pharmacogenetics and clinical syndromes. J Allergy Clin Immunol 2011; 127(3 Suppl): S60-66.
  • [17.] Bank AM, Lee JW, Krause P, Berkowitz AL. What to do when patients with epilepsy cannot take their usual oral medications. Pract Neurol 2017; 17: 66-70.
  • [18.] Berg M, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, et al. Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial. JAMA Neurol 2017; 74: 919-26.
  • [19.] Bosak M, Słowik A, Dziedzic T. Brand-to-generic oxcarbazepine switch – A prospective observational study. Epilepsy Res 2019; 151: 75-7.
  • [20.] Fanella M, Morano A, Fattouch J, Albini M, Basili LM, Casciato S, et al. Switch from originator to equivalent drug in the era of generic antiepileptic drugs: study of keppra versus epitiram clinical equivalence. Clin Neuropharmacol 2017; 40: 239-42.
  • [21.] Gha-Hyun L, Dae SJ. Brand name to generic substitution of levetiracetam in patients with epilepsy. Seizure 2018; 60: 127-31.
  • [22.] Hartley R, Aleksandrowicz J, Bowmer CJ, Cawood A, Forsythe WI. Dissolution and relative bioavailability of two carbamazepine preparations for children with epilepsy. J Pharm Pharmacol 1991; 43: 117-9.
  • [23.] Markoula S, Chatzistefanidis D, Gatzonis S, Siatouni A, Siarava E, Verentzioti A, et al. Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting. Seizure 2017; 48: 1-6.
  • [24.] Meyer MC, Straughn AB, Mhatre RM, Shah VP, Williams RL, Lesko LJ. The relative bioavailability and in vivo-in vitro correlations for four marketed carbamazepine tablets. Pharm Res 1998; 15: 1787-91.
  • [25.] Mikati M, Bassett N, Schachter S. Double-blind randomised study comparing brand-name and generic phenytoin monotherapy. Epilepsia 1992; 33: 359-65.
  • [26.] Oles KS, Penry JK, Smith LD, Anderson RL, Dean JC, Riela AR. Therapeutic bioequivalency study of brand name versus generic carbamazepine. Neurology 1992; 42: 1147-53.
  • [27.] Olsson P, Reimers A, Källén K. Quality of life after switching to generic levetiracetam – A prospective comparative study. Epilepsy Behav 2019; 96: 169-74.
  • [28.] Privitera MD, Welty TE, Gidal BE, Diaz FJ, Krebill R, Szaflarski JP, et al. Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol 2016; 15: 365-72.
  • [29.] Rathe J, Andersen M, Jarbøl DE, dePont Christensen R, Hallas J, Søndergaard J. Generic switching and nonpersistence among medicine users: a combined population-based questionnaire and register study. PLoS One 2015; 10: e0119688.
  • [30.] Reimers A, Olsson P, Nilsson J, Hoff E, Reis M, Strandberg M, et al. Impact of generic substitution on levetiracetam serum concentration – A prospective study in an outpatient setting. Epilepsy Res 2017; 134: 54-61.
  • [31.] Silpakit O, Amornpichetkoon M, Kaojarern S. Comparative study of bioavailability and clinical efficacys of carbamazepine in epileptic patients. Ann Pharmacother 1997; 31: 548-52.
  • [32.] Ting TY, Jiang W, Lionberger R, Wong J, Jones JW, Kane MA, et al. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia 2015; 56: 1415-24.
  • [33.] Vadney VJ, Kraushaar KW. Effects of switching from Depakene to generic valproic acid on individuals with mental retardation. Mental Retard 1997; 35: 468-76.
  • [34.] Van Lancker G, Van Bortel L, Delafontaine B, Boussery K, Swart E, Chahbouni A, et al. Switchability of gabapentin formulations: a randomized trial to assess bioequivalence between Neurontin and Gabasandoz on the individual subject level. Clin Pharmacol Ther 2019; 106: 195-203.
  • [35.] Yu Y, Teerenstra S, Vanmolkot F, Neef C, Burger D, Maliepaard M. Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study. Clin Pharmacol Ther 2013; 94: 519-24.
  • [36.] Karalis V, Macheras P, Bialer M. Generic products of antiepileptic drugs: a perspective on bioequivalence, bioavailability and formulation switches using Monte Carlo simulations. CNS Drugs 2014; 28: 69-77.
  • [37.] Chen C, Wright J, Gidal B, Messenheimer J. Assessing impact of real-world dosing irregularities with lamotrigine extended-release and immediate-release formulations by pharmacokinetic simulation. Ther Drug Monit 2013; 35:188-93.
  • [38.] Epilepsy Society. Generic and branded anti-epileptic drug. https://epilepsysociety.org.uk/about-epilepsy/anti-epileptic-drugs/generic-branded/
  • [39.] Davis MP, Walsh D, LeGrand SB, Naughton M. Symptom control in cancer patients: the clinical pharmacology and therapeutic role of suppositories and rectal suspensions. Supp Care Canc 2002; 10: 117-38.
  • [40.] Patel V, Cordato DJ, Malkan A, Beran RG. Rectal carbamazepine as effective long-acting treatment after cluster seizures and status epilepticus. Epilepsy Behav 2014; 31: 31-3.
  • [41.] Neuvonen PJ, Tokola O. Bioavailability of rectally administered carbamazepine mixture. Br J Clin Pharmacol 1987; 24: 839-41.
  • [42.] Holmes GB, Rosenfeld WE, Graves NM, Remmel RP, Carlson GH, Kriel RD. Absorption of valproic acid suppositories in human volunteers. Arch Neurol 1989; 46: 906-9.
  • [43.] Birnbaum AK, Kriel RL, Burkhardt RT, Remmel RP. Rectal absorption of lamotrigine compressed tablets. Epilepsia 2000; 41: 850-3.
  • [44.] Birnbaum AK, Kriel RL, Im Y, Remmel RP. Relative bioavailability of lamotrigine chewable dispersible tablets administered rectally. Pharmacotherapy 2001; 21: 158-62.
  • [45.] Gustafson MC, Penovich PE, Frost MD. Levetiracetam absorption after rectal administration: 2 case reports. Epilepsia 2005; 46(Suppl 8): 211 [Abstract 2.357]. Presented at: American Epilepsy Society Annual Meeting, Dec 2-5, 2005, Washington, USA.
  • [46.] Cagnotti G, Odore R, Gardini G, Amedeo S, Bertone I, Guerriero G, et al. Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus. BMC Vet Res 2018; 14: 189.
  • [47.] Zuberi SM, Wirrell E, Yozawitz E, Wilmshurst JM, Specchio N, Riney K, et al. ILAE classification & definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions. Epilepsia 2022; 63(6): 1349-97.
  • [48.] O’Callaghan FJ, Edwards SW, Alber FD, Hancock E, Johnson AL, Kennedy CR, et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol 2017; 16: 33-42.
  • [49.] van der Poest Clement E, Jansen FE, Braun KPJ, Peters JM. Update on drug management of refractory epilepsy in tuberous sclerosis complex. Paediatr Drugs 2020; 22: 73-84.
  • [50.] Yamamoto H, Asoh M, Murakami H, et al. Liposteroid (dexamethasone palmitate) therapy for West syndrome: a comparative study with ACTH therapy. Pediatr Neurol 1998; 18: 415-9.
  • [51.] Knupp KG, Leister E, Coryell J, Nickels KC, Ryan N, Juarez-Colunga E, et al. Pediatric epilepsy research consortium. Response to second treatment after initial failed treatment in a multicenter prospective infantile spasms cohort. Epilepsia 2016; 57: 1834-42.
  • [52.] Cardenal-Muñoz E, Auvin S, Villanueva V, Cross JH, Zuberi SM, Lagae L, et al. Guidance on Dravet syndrome from infant to adult care: road map for treatment planning in Europe. Epilepsia Open 2022; 7: 11-26.
  • [53.] Klein P, Tolbert D, Gidal BE. Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures. Epilepsy Behav 2019; 99: 106459.
  • [54.] Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 2012; 135(Pt 8): 2329-36.
  • [55.] Dalic L, Mullen SA, Roulet Perez E, Scheffer I. Lamotrigine can be beneficial in patients with Dravet syndrome. Dev Med Child Neurol 2015; 57: 200-2.
  • [56.] van den Munckhof B, Alderweireld C, Davelaar S, van Teeseling HC, Nikolakopoulos S, Braun KPJ, et al. Treatment of electrical status epilepticus in sleep: clinical and EEG characteristics and response to 147 treatments in 47 patients. Eur J Paediatr Neurol 2018; 22: 64-71.
  • [57.] Buzatu M, Bulteau C, Altuzarra C, Dulac O, Van Bogaert P. Corticosteroids as treatment of epileptic syndromes with continuous spike-waves during slow-wave sleep. Epilepsia 2009; 50(Suppl 7): 68-72.
  • [58.] Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations. Front Neurol 2017; 8: 505.
  • [59.] Asadi-Pooya AA. Lennox-Gastaut syndrome: a comprehensive review. Neurol Sci 2018; 39: 403-14.
  • [60.] Tomson T, Battino D, Bromley R, Kochen S, Meador K, Pennell P, et al. Management of epilepsy in pregnancy: a report from the International League Against Epilepsy Task Force on Women and Pregnancy. Epileptic Disord 2019; 21: 497-517.
  • [61.] Hirsch LJ, Arif H, Buchsbaum R, Weintraub D, Lee J, Chang JT, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007; 48: 1351-9.
  • [62.] Asadi-Pooya AA, Sperling MR. Clinical features of sudden unexpected death in epilepsy. J Clin Neurophysiol 2009; 26: 297-301.